10b5-1 plans for the top doggies here, creating an almost 1.3 million share overhang:
>>7-Sep-2007
Other Events
ITEM 8.01 OTHER EVENTS
In September 2007, the members of the Executive Management Team of InterMune, Inc. ("InterMune") entered into individual written trading plans in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Rule 10b5-1 allows the members of InterMune's Executive Management Team to adopt written plans for trading securities in a non-discretionary, pre-scheduled manner in order to avoid concerns about initiating stock transactions when they may be aware of non-public information. Such plans also allow them to diversify their holdings and to minimize the market effect of stock sales by spreading them out over time.
The following chart sets forth the number of shares of common stock of InterMune that each member is authorized to sell under such member's individual plan and the termination date of such plan which may be terminated earlier than the prescribed date:
Name No. Shares In Plan Plan Termination Date
Marianne Armstrong, Ph.D.,
Chief Medical Affairs &
Regulatory Officer 146,188 December 2008
Lawrence Blatt, Ph.D.,
Chief Science Officer 166,262 September 2009
Williamson Bradford, M.D.,
Ph.D.,
Vice President, Clinical
Science 133,271 December 2008
John Hodgman,
Senior Vice President and
Chief Financial Officer 68,233 November 2008
Steven Porter, M.D., Ph.D.,
Chief Medical Officer 162,766 December 2008
Howard Simon, Esq., SPHR
Senior Vice President, Human
Resources
and Corporate Services and
Associate
General Counsel 101,945 December 2008
Robin Steele, Esq.,
Senior Vice President, General
Counsel and Corporate
Secretary 104,073 December 2008
Daniel G. Welch,
President and Chief Executive
Officer 410,000 January 2009
<<
They don't seem to have buying plans . . .
Cheers, Tuck |
